ANNE SEARLS DE GROOT

Summary

Affiliation: Brown University
Country: USA

Publications

  1. pmc Tregitope peptides: the active pharmaceutical ingredient of IVIG?
    Anne S De Groot
    Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, USA EpiVax, Inc, 146 Clifford Street, Providence, RI, USA
    Clin Dev Immunol 2013:493138. 2013
  2. pmc Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes
    Leslie P Cousens
    EpiVax, Inc, 146 Clifford Street, Providence, RI 02903, USA
    J Diabetes Res 2013:621693. 2013
  3. pmc Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design
    Anne S De Groot
    Institute for Immunology and Informatics University of Rhode Island Providence, RI USA EpiVax, Inc Providence, RI USA
    Hum Vaccin Immunother 9:950-6. 2013
  4. pmc Making vaccines "on demand": a potential solution for emerging pathogens and biodefense?
    Anne S De Groot
    EpiVax, Inc Providence, RI USA Institute for Immunology and Informatics University of Rhode Island Providence, RI USA
    Hum Vaccin Immunother 9:1877-84. 2013
  5. pmc In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity
    Leslie P Cousens
    EpiVax, Inc, 146 Clifford Street, Providence, RI 02903, USA
    J Clin Immunol 33:S43-9. 2013
  6. doi request reprint Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes
    Anne S De Groot
    EpiVax, Inc, Providence, RI, USA
    Hum Vaccin Immunother 8:987-1000. 2012
  7. pmc Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV
    Anne S De Groot
    EpiVax, Inc, Providence, RI 02903, USA
    Vaccine 26:3059-71. 2008
  8. ncbi request reprint Prediction of immunogenicity for therapeutic proteins: state of the art
    Anne S De Groot
    Brown Medical School, Box G A, 97 Waterman Street, Providence, RI 02912, USA
    Curr Opin Drug Discov Devel 10:332-40. 2007
  9. ncbi request reprint Evolutionary deimmunization: an ancillary mechanism for self-tolerance?
    Anne S De Groot
    EpiVax, Inc, Providence, RI 02903, USA
    Cell Immunol 244:148-53. 2006
  10. ncbi request reprint Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences
    Anne S De Groot
    Brown University, Providence, RI 02912, United States
    Vaccine 25:8077-84. 2007

Research Grants

  1. Epitope Driven HIV Vaccine Development
    Anne De Groot; Fiscal Year: 2002
  2. Optimization of a Multivalent Tuberculosis Vaccine
    Anne De Groot; Fiscal Year: 2007
  3. Epitope-driven deimmunization of Factor VIII
    Anne De Groot; Fiscal Year: 2007
  4. Development of De-immunized Botulinum Neurotoxin Type A for Dystonia
    Anne De Groot; Fiscal Year: 2007
  5. Epitope Driven HIV Vaccine Development
    Anne De Groot; Fiscal Year: 2004
  6. 2nd Annual Vaccine Renaissance Conference, RI
    Anne De Groot; Fiscal Year: 2006
  7. Epitope Driven HIV Vaccine Development
    Anne De Groot; Fiscal Year: 2005
  8. A Genome-Derived, Epitope-Driven H. Pylori Vaccine
    Anne De Groot; Fiscal Year: 2006
  9. Novel Smallpox Vaccine Derived from VV/VAR Immunome
    Anne De Groot; Fiscal Year: 2006
  10. A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE
    Anne De Groot; Fiscal Year: 2005

Collaborators

Detail Information

Publications43

  1. pmc Tregitope peptides: the active pharmaceutical ingredient of IVIG?
    Anne S De Groot
    Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, USA EpiVax, Inc, 146 Clifford Street, Providence, RI, USA
    Clin Dev Immunol 2013:493138. 2013
    ....
  2. pmc Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes
    Leslie P Cousens
    EpiVax, Inc, 146 Clifford Street, Providence, RI 02903, USA
    J Diabetes Res 2013:621693. 2013
    ..Implementation of these defined regulatory T cell epitopes for therapy of T1D and other autoimmune diseases may lead to a paradigm shift in disease management...
  3. pmc Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design
    Anne S De Groot
    Institute for Immunology and Informatics University of Rhode Island Providence, RI USA EpiVax, Inc Providence, RI USA
    Hum Vaccin Immunother 9:950-6. 2013
    ..Should H7N9 develop pandemic potential, this analysis predicts that novel strategies for improving vaccine immunogenicity for this unique low-immunogenicity strain of avian-origin influenza will be urgently needed. ..
  4. pmc Making vaccines "on demand": a potential solution for emerging pathogens and biodefense?
    Anne S De Groot
    EpiVax, Inc Providence, RI USA Institute for Immunology and Informatics University of Rhode Island Providence, RI USA
    Hum Vaccin Immunother 9:1877-84. 2013
    ..Should such vaccines be developed, their 60-d start-to-finish timeline would represent a 2-fold faster response than the current standard. ..
  5. pmc In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity
    Leslie P Cousens
    EpiVax, Inc, 146 Clifford Street, Providence, RI 02903, USA
    J Clin Immunol 33:S43-9. 2013
    ....
  6. doi request reprint Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes
    Anne S De Groot
    EpiVax, Inc, Providence, RI, USA
    Hum Vaccin Immunother 8:987-1000. 2012
    ..Validation of these HLA-A3 epitopes conserved across time, clades, and geography supports the hypothesis that epitopes such as these would be candidates for inclusion in our globally relevant GAIA HIV vaccine constructs...
  7. pmc Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV
    Anne S De Groot
    EpiVax, Inc, Providence, RI 02903, USA
    Vaccine 26:3059-71. 2008
    ..The most immunogenic of these epitopes will be included in the GAIA multi-epitope vaccine...
  8. ncbi request reprint Prediction of immunogenicity for therapeutic proteins: state of the art
    Anne S De Groot
    Brown Medical School, Box G A, 97 Waterman Street, Providence, RI 02912, USA
    Curr Opin Drug Discov Devel 10:332-40. 2007
    ....
  9. ncbi request reprint Evolutionary deimmunization: an ancillary mechanism for self-tolerance?
    Anne S De Groot
    EpiVax, Inc, Providence, RI 02903, USA
    Cell Immunol 244:148-53. 2006
    ..Over evolutionary timescales, immune pressure may have resulted in alterations in the inherent T-cell immunogenic potential of autologous proteins...
  10. ncbi request reprint Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences
    Anne S De Groot
    Brown University, Providence, RI 02912, United States
    Vaccine 25:8077-84. 2007
    ..Based on this analysis, we predict no significant abrogation of ChimeriVax-JEV-conferred protection against circulating JEV strains...
  11. doi request reprint Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates
    Anne S De Groot
    EpiVax, Inc, University of Rhode Island, Providence, RI, USA
    Curr Opin Pharmacol 8:620-6. 2008
    ....
  12. doi request reprint Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics
    Anne S De Groot
    EpiVax, Inc, Providence, RI 02903, USA
    Clin Immunol 131:189-201. 2009
    ..Recommendations for Td immunogenicity screening and assessment provided in this article may contribute to the development of safer protein-based drugs for human use...
  13. ncbi request reprint Immunomics: discovering new targets for vaccines and therapeutics
    Anne S De Groot
    EpiVax, 146 Clifford Street, Providence, RI 02903, USA
    Drug Discov Today 11:203-9. 2006
    ..This review highlights aspects of recent immunomics research that are related to the discovery of the T-cell immunome...
  14. ncbi request reprint HIV vaccine development by computer assisted design: the GAIA vaccine
    Anne S De Groot
    TB HIV Research Laboratory, Brown University, Providence, RI 02912, USA
    Vaccine 23:2136-48. 2005
    ..These data confirm the utility of bioinformatics tools to design novel vaccines containing "immunogenic consensus sequence" T cell epitopes for a globally relevant vaccine against HIV...
  15. ncbi request reprint A comparison of two methods for T cell epitope mapping: "cell free" in vitro versus Immunoinformatics
    Timothy James Messitt
    EpiVax, Inc, Providence, RI, USA and Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, USA
    Immunome Res 7:6. 2011
    ..Although the cell-free system allows assessment of intracellular processing, the in silico approach is higher throughput, and can be performed much faster with far fewer resources...
  16. ncbi request reprint Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping
    A S De Groot
    EpiVax, Inc, Providence, RI 02906, USA
    Dev Biol (Basel) 112:71-80. 2003
    ....
  17. doi request reprint Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine
    Anne S De Groot
    EpiVax, 146 Clifford Street, Providence, RI 02903, USA
    Vaccine 27:5740-7. 2009
    ....
  18. ncbi request reprint Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach
    Anne S De Groot
    TB HIV Research Lab, Brown University, Providence, RI 02912, USA
    Vaccine 21:4486-504. 2003
    ..Putative HIV-1 CTL epitopes were selected from this list using the epitope prediction tool EpiMatrix...
  19. ncbi request reprint Immunogenicity of protein therapeutics
    Anne S De Groot
    EpiVax, Inc, 146 Clifford Street, Providence, RI 02903, USA
    Trends Immunol 28:482-90. 2007
    ..Here, we review some theories put forward to explain the immunogenicity of therapeutic proteins and describe some emerging protein-engineering approaches that might prevent the development of anti-drug antibodies...
  20. ncbi request reprint Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine
    Anne S De Groot
    TB HIV Research Lab, Brown University, Providence RI 02912, USA
    Methods 34:476-87. 2004
    ..These data confirm the utility of bioinformatics tools to select and construct novel "immunogenic consensus sequence" T cell epitopes for a globally relevant vaccine against HIV...
  21. ncbi request reprint Immuno-informatics: Mining genomes for vaccine components
    Anne S De Groot
    TB HIV Research Laboratory, Brown University, Providence, Rhode Island 02912, USA
    Immunol Cell Biol 80:255-69. 2002
    ..The present article reviews the work of several groups engaged in the development of immuno-informatics tools and illustrates the application of these tools to the process of vaccine discovery...
  22. ncbi request reprint Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine
    Julie A McMurry
    EpiVax, Inc, Providence, RI 02903, USA
    Vaccine 25:3179-91. 2007
    ..These data can aid in the development of novel epitope-based and subunit tularemia vaccines...
  23. pmc Epitope-based vaccination against pneumonic tularemia
    Stephen H Gregory
    Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, United States
    Vaccine 27:5299-306. 2009
    ..These results demonstrate the efficacy of an epitope-based tularemia vaccine and suggest that such an approach might be widely applicable to the development of vaccines specific for intracellular bacterial pathogens...
  24. pmc Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"
    Anne S De Groot
    EpiVax, Providence, RI, USA
    Blood 112:3303-11. 2008
    ..In this model, regulatory T-cell epitopes in IgG activate a subset of nT(Regs) that tips the resulting immune response toward tolerance rather than immunogenicity...
  25. doi request reprint Novel function of complement C3d as an autologous helper T-cell target
    Paul M Knopf
    Department of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912, USA
    Immunol Cell Biol 86:221-5. 2008
    ..We believe that the discovery of these autologous T cells autoreactive for C3d provides evidence supporting the 'co-signal 2' hypothesis and may offer a novel explanation of the CD21 KO paradox...
  26. ncbi request reprint T cell epitope identification for bovine vaccines: an epitope mapping method for BoLA A-11
    Anne S De Groot
    EpiVax, Inc 16 Bassett Street, Providence RI 02903, USA
    Int J Parasitol 33:641-53. 2003
    ..Furthermore, using epitope-mapping algorithms, putative T cell epitopes can be derived directly from genomic sequences, allowing researchers to circumvent labor-intensive cloning steps in the genome-to-vaccine discovery pathway...
  27. pmc The role of glutamic or aspartic acid in position four of the epitope binding motif and thyrotropin receptor-extracellular domain epitope selection in Graves' disease
    Hidefumi Inaba
    Department of Cellular and Molecular Biology, University of Rhode Island, 80 Washington Street, Providence, Rhode Island 02903, USA
    J Clin Endocrinol Metab 95:2909-16. 2010
    ..Development of Graves' disease (GD) is related to HLA-DRB1*0301 (DR3),and more specifically to arginine at position 74 of the DRB1 molecule. The extracellular domain (ECD) of human TSH receptor (hTSH-R) contains the target antigen...
  28. ncbi request reprint Developing an epitope-driven tuberculosis (TB) vaccine
    Anne S De Groot
    EpiVax, Inc, Providence, RI 02903, USA
    Vaccine 23:2121-31. 2005
    ..The systematic application of bioinformatics tools to whole genomes, in combination with in vitro methods for screening and confirming epitopes, may lead to the development of novel vaccines for infectious diseases like TB...
  29. ncbi request reprint Vaccine renaissance--from basic research to implementation
    Anne S De Groot
    EpiVax, Providence, RI 02903, USA
    Med Health R I 90:300. 2007
  30. pmc In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes
    Leonard Moise
    EpiVax, Inc, Providence, RI, USA
    Vaccine 27:6471-9. 2009
    ..This experimental validation of computational predictions illustrates the potential for immunoinformatics methods to identify candidate immunogens for a new, safer smallpox vaccine...
  31. ncbi request reprint From immunome to vaccine: epitope mapping and vaccine design tools
    Anne S De Groot
    TB HIV Research Laboratory, Brown University, International Health Institute, Box GB473, Providence, RI 02912, USA
    Novartis Found Symp 254:57-72; discussion 72-6, 98-101, 250-2. 2003
    ..More recent applications of the tools involve deriving novel vaccine candidates directly from whole genomes, an approach that has been named 'genome to vaccine'...
  32. ncbi request reprint Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice
    Julie A McMurry
    EpiVax Inc, 146 Clifford Street, Providence RI 02903, USA
    Curr Mol Med 7:351-68. 2007
    ..These experiments illustrate the use of immuno-informatics tools for vaccine development and describe a pathway for the development of a more effective, epitope-driven, immunotherapeutic vaccine for TB...
  33. ncbi request reprint A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A
    Julie A McMurry
    EpiVax, Inc, Vaccines Division, Providence, Rhode Island 02903, USA
    Hum Vaccin 4:148-57. 2008
    ..This review summarizes the critical components of effective influenza vaccines, a rational vaccine design approach, and the pertinent influenza immunology...
  34. ncbi request reprint Identification of genome-derived vaccine candidates conserved between human and mouse-adapted strains of H. pylori
    Leonard Moise
    Brown University, Providence, Rhode Island, USA
    Hum Vaccin 4:219-23. 2008
    ..pylori isolates J99 and 26695 are conserved in SS1. Epitopes conserved in SS1 were further analyzed for binding to MHC in vitro and for antigenicity in infected mice to select candidates for an epitope-based vaccine...
  35. ncbi request reprint Tularemia vaccines - an overview
    Julie A McMurry
    EpiVax, Inc, Providence, RI 02903, USA
    Med Health R I 90:311-4. 2007
    ....
  36. pmc VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone
    Leonard Moise
    EpiVax, Inc, Providence, RI, USA
    Vaccine 29:501-11. 2011
    ..Remarkably, 100% of vaccinated mice survived lethal vaccinia challenge, demonstrating that protective immunity to vaccinia does not require B cell priming...
  37. ncbi request reprint Genome-derived vaccines
    Anne S De Groot
    TB HIV Research Laboratory, Brown University, Providence, RI 20903, USA
    Expert Rev Vaccines 3:59-76. 2004
    ..This article addresses the convergence of three forces--microbial genome sequencing, computational immunology and new vaccine technologies--that are shifting genome mining for vaccines onto the forefront of immunology research...
  38. doi request reprint T cell epitope: friend or foe? Immunogenicity of biologics in context
    Constanze A Weber
    EpiVax, Providence, RI 02903, USA
    Adv Drug Deliv Rev 61:965-76. 2009
    ..In this review, we address the application of computational tools for preclinical immunogenicity assessment, the implication of the discovery of regulatory T cell epitopes, and experimental validation of those assessments...
  39. ncbi request reprint Progress towards a genome-derived, epitope-driven vaccine for latent TB infection
    Leonard Moise
    EpiVax, Inc, Providence, RI, USA
    Med Health R I 90:301-3. 2007
  40. ncbi request reprint Bioinformatics tools for identifying class I-restricted epitopes
    William Martin
    EpiVax, Inc, Providence, Rhode Island, USA
    Methods 29:289-98. 2003
    ..CTL epitopes discovered using these tools might be used to develop novel vaccines and therapeutics for the prevention and treatment of infectious diseases such as human immunodeficiency virus, hepatitis C, tuberculosis, and some cancers...
  41. ncbi request reprint Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease
    Hidefumi Inaba
    Brown University Medicine Endocrinology, Box G, Room E 308, 70 Ship Street, Providence, Rhode Island 02903, USA
    J Clin Endocrinol Metab 91:2286-94. 2006
    ..Graves' disease (GD) is characterized by autoimmunity to the TSH receptor (TSHR)...
  42. ncbi request reprint How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the past
    Anne S De Groot
    TB HIV Research Laboratory, Brown University, Providence, RI 02912, USA
    Vaccine 21:4095-104. 2003
    ..This article reviews parallels between HIV and SARS and proposes an approach that would accelerate the development of a SARS vaccine...

Research Grants18

  1. Epitope Driven HIV Vaccine Development
    Anne De Groot; Fiscal Year: 2002
    ..The final product of this joint effort will be a set of plasmids to be combined in an epitope-driven, oligonucleotide-based DNA cocktail vaccine for HIV. ..
  2. Optimization of a Multivalent Tuberculosis Vaccine
    Anne De Groot; Fiscal Year: 2007
    ..Successful completion of this work will set the stage for Phase II development that will partner the vaccine with improved recombinant BCG vaccines and assess efficacy in additional strains of HLA transgenic mice. ..
  3. Epitope-driven deimmunization of Factor VIII
    Anne De Groot; Fiscal Year: 2007
    ..The proposed reengineered protein will be evaluated in a mice that have a hemophilia as well as in mice that have a human- like immune system. ..
  4. Development of De-immunized Botulinum Neurotoxin Type A for Dystonia
    Anne De Groot; Fiscal Year: 2007
    ..Public Health Relatedness: Knowledge of the elements of botulinum neurotoxin type A that give rise to its immunogenicity will contribute to the development of improved dystonia therapy. ..
  5. Epitope Driven HIV Vaccine Development
    Anne De Groot; Fiscal Year: 2004
    ..The final product of this joint effort will be a set of plasmids to be combined in an epitope-driven, oligonucleotide-based DNA cocktail vaccine for HIV. ..
  6. 2nd Annual Vaccine Renaissance Conference, RI
    Anne De Groot; Fiscal Year: 2006
    ..This 2nd Annual conference follows a highly successful 1st Annual Vaccine Renaissance, RI that took place on June 8, 9 2005. More than 80 participants attended that 1st conference from the New England region and beyond. ..
  7. Epitope Driven HIV Vaccine Development
    Anne De Groot; Fiscal Year: 2005
    ..The final product of this joint effort will be a set of plasmids to be combined in an epitope-driven, oligonucleotide-based DNA cocktail vaccine for HIV. ..
  8. A Genome-Derived, Epitope-Driven H. Pylori Vaccine
    Anne De Groot; Fiscal Year: 2006
    ..pylori disease as our correlate of efficacy. ..
  9. Novel Smallpox Vaccine Derived from VV/VAR Immunome
    Anne De Groot; Fiscal Year: 2006
    ....
  10. A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE
    Anne De Groot; Fiscal Year: 2005
    ..abstract_text> ..
  11. Epitope Driven HIV Vaccine Development
    Anne De Groot; Fiscal Year: 2004
    ..The final product of this joint effort will be a set of plasmids to be combined in an epitope-driven, oligonucleotide-based DNA cocktail vaccine for HIV. ..
  12. Epitope Driven HIV Vaccine Development
    Anne De Groot; Fiscal Year: 2003
    ..The final product of this joint effort will be a set of plasmids to be combined in an epitope-driven, oligonucleotide-based DNA cocktail vaccine for HIV. ..
  13. Epitope Driven HIV Vaccine Development
    Anne De Groot; Fiscal Year: 2003
    ..The final product of this joint effort will be a set of plasmids to be combined in an epitope-driven, oligonucleotide-based DNA cocktail vaccine for HIV. ..